NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

APDN

Applied DNA Sciences Inc NASDAQ Capital Market
$6.05
Open: $6.26 High: $6.4 Low: $5.85 Close: $5.95
Range: 2021-04-19 - 2021-04-20
Volume: 319,897
Market: Extended-hours
Powered by Finage Stock APIDelayed data
APDN
Applied DNA Sciences Inc 50 Health Sciences Drive Stony Brook NY, 11790 http://www.adnas.com
Applied DNA Sciences Inc creates security solutions addressing the challenges of supply chain security, brand protection or law enforcement applications.
  • CEO: James A. Hayward
  • Employees: 57
  • Sector: Industrials
  • Industry: Consulting & Outsourcing
APDN News
Latest news about the APDN
  • Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines

    Preliminary results of phase I clinical trial yields high titers of SARS-CoV-2 neutralizing antibodies from all cohort members.

    View More →
  • Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

    Applied DNA CEO discusses relevance of DNA-based cotton traceability in textile manufacturing in interview with BBC.

    View More →
  • Applied DNA Sciences (APDN) Moves 13.2% Higher: Will This Strength Last?

    Applied DNA Sciences (APDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    View More →
  • Applied DNA Sciences (APDN) Upgraded to Buy: Here's What You Should Know

    Applied DNA Sciences (APDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    View More →
  • Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

    Applied DNA and Northwell establish a real-time surveillance program to track and identify SARS-CoV-2 mutations and variants of concern.

    View More →
  • Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

    Clay Shorrock rejoins the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Exec. Dir., B. Dev.

    View More →
  • Applied DNA Sciences, Inc. (NASDAQ:APDN): Is Breakeven Near?

    Applied DNA Sciences, Inc. ( NASDAQ:APDN ) is possibly approaching a major achievement in its business, so we would...

    View More →
  • Applied DNA Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests

    Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the receipt of a purchase order for its Linea™ COVID-19 Assay Kit (the "Assay Kit") and consumables to conduct 10,000 tests under a Master Services Agreement with an existing customer. The Company expects to deliver most of the purchase order in the current fiscal quarter ending March 31, 2021 with the balance to be delivered in the following fiscal quarter. This blanket purchase order represents the third such order from the customer for the purpose of conducting pooled COVID-19 surveillance testing.

    View More →
  • Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to Boost SARS-CoV-2 Variant Detection and Tracking Nationally

    Applied DNA Launches Selective Genomic Surveillance Screening Platform for SARS-CoV-2 Variant Detection and Tracking.

    View More →
  • Applied DNA to Participate in Upcoming Conferences

    Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences.

    View More →
  • Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

    If the veterinary vaccine candidate demonstrates effectiveness, the two companies intend to apply to USDA to enable commercial vet sales under APHIS.

    View More →
  • Looking Into Applied DNA Sciences's Return On Capital Employed

    Applied DNA Sciences (NASDAQ:APDN) reported Q1 sales of $1.62 million. Earnings fell to a loss of $2.97 million, resulting in a 26.64% decrease from last quarter. In Q4, Applied DNA Sciences brought in $314.00 thousand in sales but lost $4.05 million in earnings. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Applied DNA Sciences's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Applied DNA Sciences posted an ROCE of -0.52%. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future. View more earnings on APDN Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. For Applied DNA Sciences, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions. Q1 Earnings Insight Applied DNA Sciences reported Q1 earnings per share at $-0.56/share, which did not meet analyst predictions of $-0.54/share. See more from BenzingaClick here for options trades from Benzinga12 Information Technology Stocks Moving In Thursday's Pre-Market Session12 Information Technology Stocks Moving In Friday's Pre-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Applied DNA Granted U.S. Patent Covering Methods of Utilizing DNA Tagged Submicron Particles for Authentication

    Newly granted patent has applicability in the DNA tagging of pharmaceutical, nutraceutical and personal care excipients.

    View More →
  • Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM College

    NYC-based LIM College joins other education institutions relying on Applied DNA's safeCircle service to ensure a safe learning environment.

    View More →
  • Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates

    Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -12.73% and 15.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range

    Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range

    View More →
  • Applied DNA Sciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Applied DNA Sciences, Inc. (NASDAQ:APDN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on February 11, 2021 at 4:30 PM Eastern Time.

    View More →
  • Applied DNA and Cytocheck Detect First Instance of SARS-CoV-2 B.1.1.7 Variant in Kansas

    Linea(TM) COVID-19 Assay Kit utilized in genomic surveillance mode detects first instance of SARS-CoV-2 B.1.1.7 (UK) variant in Kansas.

    View More →
  • Earnings Preview for Applied DNA Sciences

    Applied DNA Sciences (NASDAQ:APDN) announces its next round of earnings this Thursday, February 11. Here is Benzinga's look at Applied DNA Sciences's Q1 earnings report. Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Based on management's projections, Applied DNA Sciences analysts modeled for a loss of $0.54 per share on sales of $1.36 million. Applied DNA Sciences EPS in the same period a year ago totaled $1.12. Revenue was $633.52 thousand. Why Analyst Estimates And Earnings Surprises Are Important Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values. View more earnings on APDN If the company were to match the consensus estimate when it reports Thursday, EPS would be up 51.79%. Revenue would be up 114.67% from the year-ago period. The company's reported EPS has stacked up against analyst estimates in the past like this: Quarter Q4 2020 Q3 2020 Q2 2020 Q1 2020 EPS Estimate -0.52 -0.67 -0.77 -1.24 EPS Actual -0.82 -0.72 -0.79 -1.12 Revenue Estimate 710.00 K 800.00 K 950.00 K 750.00 K Revenue Actual 314.00 K 431.52 K 552.47 K 633.52 K Stock Performance Shares of Applied DNA Sciences were trading at $10.3 as of February 09. Over the last 52-week period, shares are up 215.85%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Applied DNA Sciences is scheduled to hold the call at 16:30:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaPreview: Pixelworks's EarningsGoDaddy's Earnings: A Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Applied DNA Schedules Fiscal 2021 First Quarter Financial Results Conference Call and Webcast for Thursday, February 11, 2021

    Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar’ section of the Company’s corporate website and embedded into the live webcast.

    View More →